{"schema_version":"secwatch.filing_event.v1","accession":"0001477932-26-000714","form_type":"8-K","ticker":"VNRX","cik":"0000093314","company_name":"VOLITIONRX LTD","filed_at":"2026-02-09T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.079291+00:00","generated_at":"2026-05-16T04:01:12.600777+00:00","sec_items":["3.01","8.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"VolitionRx receives NYSE American non-compliance notice for stockholders' equity; must submit plan by March 8, 2026","bullets":["Received NYSE American notice on Feb 6, 2026 for failing $2M, $4M, $6M stockholders' equity thresholds due to sustained losses.","Must submit compliance plan by March 8, 2026; deadline to regain compliance is August 6, 2027.","Stock will trade under VNRX with \".BC\" designation indicating \"below compliance.\"","If plan not submitted or accepted, NYSE American will commence delisting proceedings.","No immediate impact on listing or business operations; company intends to submit a plan."],"urls":{"canonical":"https://secwatch.observer/filing/0001477932-26-000714","json":"https://secwatch.observer/filing/0001477932-26-000714.json","markdown":"https://secwatch.observer/filing/0001477932-26-000714.md","text":"https://secwatch.observer/filing/0001477932-26-000714.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/93314/000147793226000714/0001477932-26-000714-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/93314/000147793226000714/vnrx_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T04:01:12.600777+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"748e7f69296b867451463f4fb1d9d44e8e876b66","claim":"VOLITIONRX LTD received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1003(a)(iii)).","evidence_excerpt":"February 6, 2026, VolitionRx Limited (the “Company”) received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the “Company Guide”) requiring a company to have stockholders’ equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders’ equit","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/93314/000147793226000714/0001477932-26-000714-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nyse american"},{"label":"Notice","value":"noncompliance notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"1003(a)(i), 1003(a)(ii), 1003(a)(iii)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}